Reply to thread

Message

Steven Yatomi-Clarke, CEO of Aussie biotech Prescient Therapeutics (PTX), is holding a special investor briefing online this Wednesday evening 12 August at 7pm AEST.

Steven will discuss:
PTX-100 and PTX-200 trial programmes
Enhancements to Cell Therapy Capabilities and related intellectual property
PTX's next-generation CAR-T asset (OmniCAR) with the global and worldwide licence agreement it has with the University of Pennsylvania.
This is a live and interactive online session, and participants are encouraged to ask questions.

Register for this free event here: https://reachmarkets.com.au/ptx-investorbriefing/

[QUOTE="System, post: 1087469, member: 36329"] Steven Yatomi-Clarke, CEO of Aussie biotech Prescient Therapeutics (PTX), is holding a special investor briefing online this Wednesday evening 12 August at 7pm AEST. Steven will discuss: [LIST] [*]PTX-100 and PTX-200 trial programmes [*]Enhancements to Cell Therapy Capabilities and related intellectual property [*]PTX's next-generation CAR-T asset (OmniCAR) with the global and worldwide licence agreement it has with the University of Pennsylvania. [/LIST] [I]This is a live and interactive online session, and participants are encouraged to ask questions.[/I] Register for this free event here: [URL]https://reachmarkets.com.au/ptx-investorbriefing/[/URL] [/QUOTE]

Verification